Welcome to our dedicated page for Clorox Co Del SEC filings (Ticker: CLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clorox Company (NYSE: CLX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a consumer products manufacturer in the polish and other sanitation good manufacturing industry. This SEC filings page aggregates those disclosures and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
Key filings for CLX include annual reports on Form 10-K, which typically describe the company’s business segments—Health and Wellness, Household, Lifestyle and International—along with risk factors, discussion of strategy and detailed financial statements. Quarterly reports on Form 10-Q update investors on interim performance, including segment results, margin drivers, cash flow and the impact of initiatives such as the U.S. enterprise resource planning (ERP) transition and portfolio changes like the divestiture of the Better Health Vitamins, Minerals and Supplements business.
Clorox also uses current reports on Form 8-K to disclose material events. Recent 8-K filings have covered quarterly and annual financial results, supplemental financial information, and matters submitted to a shareholder vote at the annual meeting, including director elections, advisory votes on executive compensation and ratification of the independent registered public accounting firm. Other 8-Ks may address leadership changes or other significant corporate developments.
The company’s proxy statement on Form DEF 14A provides additional detail on governance, board composition, executive compensation, strategic priorities such as the IGNITE strategy and oversight of areas like risk management and sustainability. For those interested in ownership and compensation, this document is a primary source.
On this page, filings are updated as they are released to EDGAR. AI-generated highlights and plain-language explanations help clarify complex topics such as non-GAAP measures (for example, organic sales growth, adjusted EBIT and adjusted EPS), the effects of the ERP transition on reported results, and the rationale behind portfolio actions. Users can also review any available insider-related disclosures, such as Form 4 filings, to see reported transactions by directors and officers.
Whether you are analyzing Clorox’s segment performance, reviewing governance practices, or tracking shareholder votes and executive compensation, this filings hub offers structured access to the company’s regulatory record with tools designed to make lengthy documents more approachable.
Clorox Co. director deferred stock unit grants and reinvestments
A director of Clorox Co. reported multiple acquisitions of deferred stock units tied to Clorox common stock during 2025. On several dates, including 02/14/2025, 05/09/2025, 08/29/2025, and 11/06/2025, small fractional amounts of deferred stock units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, each at an exercise price of $0.0000 and on a 1-for-1 basis into Clorox stock.
On 12/31/2025, the director received an additional 1,637.8577 deferred stock units as an annual award under the 2005 Stock Incentive Plan, also with a conversion price of $0.0000. Following these transactions, the director beneficially owned a total of 4,471.9997 deferred stock units, which will be settled 100% in Clorox stock upon retirement or other termination of service as a director.
Clorox Co. director reported routine equity-based compensation and fee deferrals in the form of deferred stock units. On 11/06/2025, the director acquired 8.9351 deferred stock units tied to Clorox common stock through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, bringing the beneficially owned balance to 774.7598 units.
On 12/31/2025, the director received an annual award of 1,637.8577 deferred stock units under the 2005 Stock Incentive Plan, increasing holdings to 2,412.6175 units, and an additional 334.7218 deferred stock units in lieu of cash quarterly director fees, for a new total of 2,747.3393 units. All deferred stock units are scheduled to be settled 100% in Clorox stock after the director retires or otherwise leaves the board.
The Clorox Company reported a routine equity grant to a director. On 12/31/2025, the director received an annual award of 1-for-1 Deferred Stock Units under the company’s 2005 Stock Incentive Plan. The transaction, reported on a Form 4 for one reporting person, shows 1,637.8577 Deferred Stock Units credited at a price of $0.0000 per unit.
The Deferred Stock Units are tied to Clorox common stock and will be settled 100% in Clorox shares in connection with the director’s retirement or other termination of board service. The filing characterizes this as an annual award, reflecting ongoing non-cash compensation for board service rather than an open-market purchase or sale.
The Clorox Company director reports a routine stock-based compensation grant. A board member received an annual award of 825.0862 Deferred Stock Units on 12/31/2025 under the company’s 2005 Stock Incentive Plan. Each unit is described as a 1-for-1 right tied to a share of Clorox common stock, with a stated price of $0.0000 per unit, indicating this is a compensation award rather than an open‑market purchase. The filing states these Deferred Stock Units will be settled entirely in Clorox stock when the director retires or otherwise leaves the board, so the director’s economic interest in the company increases but actual shares will be issued in the future.
Clorox Co (CLX) reported an insider equity transaction by its EVP and Chief Operating Officer. On 12/12/2025, the executive had 255 shares of Clorox common stock withheld at $102.83 per share in a transaction coded F, which the company explains was to satisfy employment tax obligations tied to previously granted restricted stock units for a retirement-eligible employee. Following this withholding, the executive directly beneficially owns 69,058 shares of Clorox common stock.
Clorox Company reported that its Chief Executive Officer and director had 829 shares of common stock withheld on December 12, 2025 at a price of $102.83 per share. According to the explanation, the company withheld these shares to satisfy employment tax obligations applicable to restricted stock units previously granted to retirement eligible employees. After this tax-related share withholding, the executive directly beneficially owns 201,161 shares of Clorox common stock.
Clorox Company executive reports a small share withholding for taxes. A vice president who serves as CAO and corporate controller reported that on 12/12/2025 the company withheld 24 shares of common stock at $102.83 per share. This withholding was used to satisfy employment tax obligations tied to previously granted restricted stock units for retirement-eligible employees.
After this transaction, the officer beneficially owns 6,968 Clorox shares directly and 100 shares indirectly through a trust of a parent, indicating the filing reflects routine tax-related share withholding rather than an open-market sale.
Clorox Company reported that its EVP - Chief Admin Officer had 310 shares of common stock withheld on 12/12/2025 to cover employment tax obligations tied to previously granted restricted stock units. The shares were valued at $102.83 each for this tax-related withholding. Following this routine transaction, the officer directly beneficially owns 37,970 shares of Clorox common stock.
The Clorox Company executive reported a routine tax-related share withholding. On 12/12/2025, the EVP–Group President, Health & Hygiene had 133 shares of Clorox common stock disposed of at $102.83 per share in a transaction coded "F," which denotes shares applied to obligations such as taxes. According to the explanation, the Company withheld these shares to satisfy employment tax obligations tied to restricted stock units previously granted to "retirement eligible employees." After this transaction, the executive directly beneficially owned 35,000 shares of Clorox common stock.
Clorox Co. reported a small insider share disposition by an executive officer who serves as EVP - Executive Chief of Staff. On 12/12/2025, 65 shares of Clorox common stock were disposed of at $102.83 per share in a transaction coded “F,” reflecting shares withheld by the company to cover employment tax obligations on previously granted restricted stock units to a retirement-eligible employee.
After this tax-related withholding, the executive beneficially owns 32,138 shares of Clorox common stock in direct ownership.